Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Barry Ticho Sells 1,745 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 1,745 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $10.00, for a total transaction of $17,450.00. Following the sale, the insider now owns 32,253 shares in the company, valued at approximately $322,530. This trade represents a 5.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Barry Ticho also recently made the following trade(s):

• On Tuesday, June 3rd, Barry Ticho sold 6,471 shares of Stoke Therapeutics stock. The stock was sold at an average price of $10.03, for a total transaction of $64,904.13.
• On Tuesday, March 18th, Barry Ticho sold 3,884 shares of Stoke Therapeutics stock. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28.

Stoke Therapeutics Trading Up 2.4%

Shares of STOK traded up $0.26 during mid-day trading on Friday, reaching $11.14. The company had a trading volume of 463,035 shares, compared to its average volume of 705,353. The stock has a market cap of $608.21 million, a price-to-earnings ratio of -5.30 and a beta of 1.09. The firm has a fifty day simple moving average of $8.77 and a 200-day simple moving average of $9.64. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. As a group, equities analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently made changes to their positions in STOK. GAMMA Investing LLC raised its stake in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after acquiring an additional 5,084 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Stoke Therapeutics in the 4th quarter valued at $63,000. AlphaQuest LLC purchased a new position in shares of Stoke Therapeutics in the 1st quarter valued at $72,000. US Bancorp DE raised its stake in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company's stock valued at $75,000 after acquiring an additional 11,108 shares during the period. Finally, Fox Run Management L.L.C. purchased a new position in shares of Stoke Therapeutics in the 1st quarter valued at $92,000.

Wall Street Analyst Weigh In

STOK has been the topic of a number of analyst reports. Chardan Capital restated a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, HC Wainwright decreased their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $23.20.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.